ACET — Adicet Bio, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1720580 ·
Last close
$2.78
Market Cap
$26.03M
52W High
$11.15
52W Low
$2.60
ADV30
262,415
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -19,796,000 -18,878,000 128,946,000 27,111,000 26,249,000
Jun 2026 0 — -22,301,000 -21,358,000 148,166,000 33,131,000 28,028,000
Mar 2026 0 — -21,570,000 -20,244,000 169,382,000 36,245,000 29,317,000
Dec 2025 0 — -31,886,000 -30,516,000 192,355,000 38,918,000 33,145,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-84,529,000
Investing CF
$7,831,000
Financing CF
$75,075,000
CapEx
$-495,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-11.45
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-656,299,000
Inventory
—
Receivables
$439,000
ST Investments
$85,059,000
EBIT TTM
$-98,750,000
Pretax Income TTM
$-98,831,000
Interest Exp TTM
$81,000
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -122,114,000 -116,803,000 192,355,000 33,145,000 159,210,000 -95,246,000
Dec 2024 0 -127,615,000 -117,122,000 220,219,000 33,610,000 186,609,000 -92,378,000
Dec 2023 0 -132,576,000 -142,658,000 207,295,000 37,120,000 170,175,000 -93,717,000
Dec 2022 24,990,000 -72,551,000 -69,790,000 330,690,000 38,352,000 292,338,000 -44,765,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-98,974,000
OpCashFlow TTM
—
Assets (Latest)
$148,166,000
Forward EPS
$-4.04

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $2.50 · call volume: 100 · put volume: 0

Peers — same industry

TickerNameMarket CapLastDaily %
RMTI ROCKWELL MEDICAL, INC. $26.25M $6.61 —
BETRF BetterLife Pharma Inc. $25.64M $0.15 —
ABVC ABVC BIOPHARMA, INC. $25.36M $0.94 —
BIOE Bio Essence Corp $25.29M $0.47 —
MIRA MIRA PHARMACEUTICALS, INC. $26.89M $0.64 —

News headlines (Yahoo Finance, 1h cache)

Adicet Bio (ACET) Stock Fair Value Moves Lower After Prula Cel Lupus Data
2026-11-11 03:11 · Yahoo
Adicet Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-05 21:10 · Yahoo
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2026-10-30 21:38 · Yahoo
Adicet Bio to Participate in Upcoming Investor Conferences
2026-10-22 20:00 · Yahoo
Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
2026-10-03 01:02 · Yahoo
Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance
2026-09-28 14:54 · Yahoo
Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients
2026-09-28 12:13 · Yahoo
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
2026-09-25 20:00 · Yahoo
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
2026-09-03 13:55 · Yahoo
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
2026-09-03 13:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.